NAP
DGX icon

New Amsterdam Partners’s Quest Diagnostics DGX Stock Holding History

New Amsterdam Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,250
Closed -$732K – 127
2016
Q1 		$732K Sell
10,250
-937
-8% -$62.8K 0.08% 95
2015
Q4 		$796K Sell
11,187
-3,235
-22% -$217K 0.08% 93
2015
Q3 		$887K Buy
14,422
+1,252
+10% +$87.5K 0.09% 91
2015
Q2 		$955K Sell
13,170
-38,657
-75% -$2.85M 0.08% 90
2015
Q1 		$3.98M Buy
51,827
+3,939
+8% +$282K 0.32% 71
2014
Q4 		$3.21M Buy
+47,888
New +$3.02M 0.28% 91

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

New Amsterdam Partners's DGX Position: Q2 2016 in Review

New Amsterdam Partners sold out of Quest Diagnostics (DGX) in Q2 2016, closing a stake of 10,250 shares — an estimated $732K sold.

New Amsterdam Partners first reported a position in DGX in Q4 2014 and held it in 6 quarters. The position peaked at $3.98M in Q1 2015. 558 funds tracked by Wall St. Rank hold DGX as of Q2 2016.

  • New Amsterdam Partners reported no remaining Quest Diagnostics position as of Q2 2016 after selling out during the quarter.
  • New Amsterdam Partners sold 10,250 Quest Diagnostics shares in Q2 2016, an estimated $732K.
  • New Amsterdam Partners first reported a position in Quest Diagnostics in Q4 2014 and held it in 6 quarters.
  • New Amsterdam Partners's Quest Diagnostics position peaked at $3.98M in Q1 2015.
  • 558 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2016.

Based on New Amsterdam Partners's 13F filing for Q2 2016, filed 1 Aug 2016.